| Business Summary | | Pharmos
Corporation
is
a
bio-pharmaceutical
company
that
discovers
and
develops
novel
therapeutics
to
treat
a
range
of
inflammatory
and
neurological
disorders,
such
as
traumatic
brain
injury
and
stroke.
The
Company
has
an
extensive
portfolio
of
drug
candidates
under
development,
as
well
as
discovery,
preclinical
and
clinical
capabilities.
Dexanabinol,
the
Company's
lead
central
nervous
system
product
aimed
initially
at
treating
severe
head
trauma
and
stroke,
is
currently
undergoing
a
pivotal
Phase
III
clinical
trial
for
severe
traumatic
brain
injury
in
Europe. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Pharmos
Corp.
is
a
pharmaceutical
co.
engaged
in
the
research
and
development
of
novel
drugs
based
on
innovative
drug
delivery
technologies.
PARS
portfolio
of
drugs
targets
diseases
of
the
eye
and
the
Central
Nervous
System.
For
the
six
months
ended
6/30/01,
revenues
rose
24%
to
$2.6
million.
Net
loss
applicable
to
Common
rose
86%
to
$5.1
million.
Revenues
reflect
market
share
gains.
Higher
loss
reflects
increased
staffing
levels
and
activity
in
the
cannabinoid
program. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Haim Aviv, Ph.D., 61 Chairman,
CEO and Chief Scientist | $322K | $781K | Gad Riesenfeld, Ph.D., 57 Pres,
COO, Sec. | 285K | 481K | Robert Cook, 45 CFO,
Exec. VP | 229K | 215K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|